CONNECT
[/et_pb_text][et_pb_image src=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9mZWF0dXJlZF9pbWFnZSIsInNldHRpbmdzIjp7fX0=@” _builder_version=”4.16″ _dynamic_attributes=”src” _module_preset=”default” max_height=”200px” global_colors_info=”{}”][/et_pb_image][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]AZD0530 in Mild Alzheimer’s Disease
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_testimonial portrait_url=”https://dev-atri-multisite.pantheonsite.io/wp-content/uploads/2022/03/c-v-d-1-e1646697360804.jpeg” _builder_version=”4.16″ _module_preset=”_initial” max_width=”1000px” module_alignment=”center” custom_padding=”54px|30px|54px||true|false” global_colors_info=”{}”]“My colleagues and I were honored to be able to test this important therapeutic idea developed in basic research. Many of us have been personally touched by Alzheimer’s. We are so grateful to those who participated in this study.”
Chris van Dyck, M.D.
CONNECT Principal Investigator
Professor of Psychiatry, Neurology, and Neuroscience
Director, Alzheimer’s Disease Research Unit
Director, Yale Alzheimer’s Disease Research Center
Director, Division of Aging and Geriatric Psychiatry Yale School of Medicine
San Francisco VA Medical Center
Overview
[/et_pb_text][et_pb_text _builder_version=”4.16″ _module_preset=”default” max_width=”900px” module_alignment=”center” global_colors_info=”{}”]On behalf of Yale University and the Alzheimer’s Therapeutic Research Institute (ATRI), we want to thank everyone for their participation in the FYN (Connect) study to evaluate the drug AZD0530 treatment was found to be safe and well-tolerated by most individuals at the doses tested (100 or 125mg daily).
However, treatment with AZD0530, did not demonstrate any benefit for the primary aim of the study, which was to preserve brain function as measured by the PET scans. It also did not show an advantage in the assessments of memory and daily functioning. Additional analyses are in progress, and the results will be reported to all clinical site, principal investigators.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}” global_module=”2826″ saved_tabs=”all”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”/studies/” button_text=”Back to STUDIES” _builder_version=”4.19.2″ _module_preset=”d2822aae-eec8-457e-833b-5377df655e55″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section]